Drug Discovery
ByWhat Does SoftBank’s $41 Billion Bet on OpenAI Signal for the Future of Biopharma, Healthcare, and AI Infrastructure?
Global – December 2025 — SoftBank’s $41 billion investment in OpenAI represents one of the most consequential capital…
Did Ophthalmic Therapy Approvals in 2025 Redefine Vision Care—and Set the Stage for Accelerated Innovation in 2026?
Global – December 2025 — The ophthalmology therapeutic area entered a renewed phase of innovation in 2025, driven…
Did Metabolic Therapy Approvals in 2025 Reset the Standard of Care—and Ignite a New Growth Cycle in 2026?
Global – December 2025 — The metabolic therapeutic area emerged as one of the most transformative forces in…
Did Renal Therapy Approvals in 2025 Redefine Kidney Disease Management—and Set the Stage for Breakthroughs in 2026?
Global – December 2025 — The renal therapeutic area emerged as a renewed focus of innovation in 2025,…
Is Pfizer’s $10 Billion Metsera Acquisition at JPM2026 a Defining Move in the Obesity and Cardiometabolic Race?
San Francisco / New York | January 2026 Pfizer has made a decisive strategic move to expand its…
Is Amgen Bolstering Its Oncology Pipeline at JPM 2026 with an $840 Million Dark Blue Therapeutics Acquisition?
Thousand Oaks, U.S. | January 2026 Amgen has expanded its oncology growth strategy with the acquisition of Dark…
